BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update
NEW YORK, Aug. 8, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call and webcast to update shareholders on financial results for the second quarter of 2025, at 8.30 a.m. Eastern Time on August 14, 2025.
BrainStorm's President and Chief Executive Officer, Chaim Lebovits, will provide the update. Hartoun Hartounian, PhD, Chief Operating Officer, Bob Dagher, MD, Chief Medical Officer, and Alla Patlis, Interim Chief Financial Officer, will also participate in the call. Following the prepared remarks, there will be a Q&A session with the investment community.
Participants are encouraged to submit their questions in advance of the call by sending them to: q@brainstorm-cell.com. Questions should be submitted by 10:00 a.m. Eastern Time on August 12, 2025.
The investment community may participate in the conference call by dialing the following numbers:
Investor dial in:U.S. Toll Free: 877-545-0320 International: 973-528-0002
Participant Access Code: 601260 Webcast URL: https://shorturl.at/xrBQQ
Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available until August 28, 2026.
Teleconference Replay Number:
Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 52831
About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection.
NurOwn® is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the "Floor Effect" - a critical challenge in measuring clinical outcomes in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging area of regenerative medicine. To learn more, visit www.brainstorm-cell.com.
Notice Regarding Forward-Looking Statements This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), Special Protocol Assessment (SPA), the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.
CONTACTS
Investors:Michael Wood Phone: +1 646-597-6983 mwood@lifesciadvisors.com
Media:Uri Yablonka, Chief Business Officer Phone: +1 917-284-2911 uri@brainstorm-cell.com
Logo - https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/brainstorm-to-announce-second-quarter-financial-results-and-provide-a-corporate-update-302524833.html
SOURCE BrainStorm Cell Therapeutics Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Why do we sneeze? Why do your eyes close? A pediatric nurse explains the science of sneezing
Curious Kids is a series for children of all ages. If you have a question you'd like an expert to answer, send it to curiouskidsus@ Why do we sneeze? – Naomi, 9, San Francisco, California Why do people sneeze with their eyes closed? Is there a way for people to sneeze with their eyes open? – Carlos, 11, Riverview, Florida Why do adults make a loud noise when they sneeze? – Artie, 8, Brooklyn, New York Aaaaa-choo! While your first thought may be to say 'Gesundheit!' your second might be to ask: 'Where did that sneeze come from?' Sneezing is a phenomenon that occurs in both people and animals. It happens when your body forcibly expels air from your lungs through your nose and mouth. Most of the time, sneezing happens when something infectious, like a virus or bacteria, or irritating, like an allergen or chemical, enters your nostrils. Your body uses sneezing as a defense mechanism to clear your nose of mucus – also known as snot – and prevent foreign objects and particles from entering your airway. But sneezing can also occur as a reaction to more unusual stimuli. Chemicals like piperine or capsaicin found in foods like black pepper and chili peppers can irritate the nerve endings inside your nose's mucous membranes and lead to a sneeze. Another type of sneeze is psychogenic, meaning it's caused by something more mental than physical. Though not fully understood, researchers believe it occurs when a strong emotion triggers your brain to send a chemical signal to your nose that makes you sneeze. And finally, about one in four people experience something called photosneezia, or a photic sneeze reflex, where light, particularly sunlight, can trigger a sneeze. Is it possible to sneeze without closing your eyes? Despite a popular myth that sneezing with your eyes open will make them pop out, it's actually possible to keep your eyes open when you sneeze. Closing your eyes during a sneeze is an autonomic reflex. This means that your body does it without you needing to consciously think about it. Scientists believe that your body makes your eyes close when you sneeze to decrease the likelihood of germs getting into them. It's possible to fight that reflex and intentionally keep your eyes open. But it might be better to keep them closed to avoid getting the germs you expelled into your eyes. Why do you make noises when you sneeze? Some people have very loud sneezes, while others have more delicate sneezes. The noise you make when you sneeze is a result of air escaping your mouth or nose. Generally, the more air you breathe in, the louder your sneeze will be. Like closing your eyes, inhaling prior to a sneeze is largely a reflex but could be consciously controlled as well. Some people even hold in or 'swallow' their sneezes, though health experts don't recommend this due to potential risk for injury. Some sneezes can be so powerful they expel mucous droplets as forcefully as 100 miles per hour! What is proper sneezing etiquette? Although sneezing is sometimes just a reflex, or the result of an allergy or chemical irritation, sneezing can also be a symptom of a contagious illness or upper respiratory infection. When you feel the urge to sneeze, best practice is to sneeze into a tissue or your sleeve to catch the germs that may come out with the air you expelled. If you caught your sneeze with a tissue or touched your nose and mouth, good hand hygiene, like washing with soap and water or using hand sanitizer, is especially important to help prevent spreading germs. Whether you sneeze with your eyes open or closed, loudly or quietly, covering your mouth and nose when you sneeze and washing your hands for 20 seconds after can help protect others from getting sick. Hello, curious kids! Do you have a question you'd like an expert to answer? Ask an adult to send your question to CuriousKidsUS@ Please tell us your name, age and the city where you live. And since curiosity has no age limit – adults, let us know what you're wondering, too. We won't be able to answer every question, but we will do our best. This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Meg Sorg, Purdue University Read more: Why hand-washing really is as important as doctors say Why do people faint? Pollen is getting worse, but you can make things better with these tips from an allergist Meg Sorg does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment. Solve the daily Crossword
Yahoo
9 minutes ago
- Yahoo
Fidelis Insurance Holdings' (NYSE:FIHL) Shareholders Will Receive A Bigger Dividend Than Last Year
Fidelis Insurance Holdings Limited (NYSE:FIHL) will increase its dividend on the 26th of September to $0.15, which is 50% higher than last year's payment from the same period of $0.10. This makes the dividend yield 2.4%, which is above the industry average. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Fidelis Insurance Holdings' Projections Indicate Future Payments May Be Unsustainable Estimates Indicate Fidelis Insurance Holdings' Could Struggle to Maintain Dividend Payments In The Future Fidelis Insurance Holdings' Future Dividends May Potentially Be At Risk While it is great to have a strong dividend yield, we should also consider whether the payment is sustainable. Fidelis Insurance Holdings is not generating a profit, but its free cash flows easily cover the dividend, leaving plenty for reinvestment in the business. We generally think that cash flow is more important than accounting measures of profit, so we are fairly comfortable with the dividend at this level. EPS is forecast to rise very quickly over the next 12 months. Assuming the dividend continues along recent trends, we could see the payout ratio reach 222%, which is on the unsustainable side. View our latest analysis for Fidelis Insurance Holdings Fidelis Insurance Holdings Doesn't Have A Long Payment History It's not possible for us to make a backward looking judgement just based on a short payment history. This doesn't mean that the company can't pay a good dividend, but just that we want to wait until it can prove itself. Fidelis Insurance Holdings Could Grow Its Dividend The company's investors will be pleased to have been receiving dividend income for some time. Fidelis Insurance Holdings has impressed us by growing EPS at 8.0% per year over the past five years. Even though the company isn't making a profit, strong earnings growth could turn that around in the near future. As long as the company becomes profitable soon, it is on a trajectory that could see it being a solid dividend payer. In Summary Overall, this is probably not a great income stock, even though the dividend is being raised at the moment. The company is generating plenty of cash, which could maintain the dividend for a while, but the track record hasn't been great. We would probably look elsewhere for an income investment. Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. Still, investors need to consider a host of other factors, apart from dividend payments, when analysing a company. As an example, we've identified 1 warning sign for Fidelis Insurance Holdings that you should be aware of before investing. Is Fidelis Insurance Holdings not quite the opportunity you were looking for? Why not check out our selection of top dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Results: NCR Atleos Corporation Exceeded Expectations And The Consensus Has Updated Its Estimates
Explore NCR Atleos's Fair Values from the Community and select yours NCR Atleos Corporation (NYSE:NATL) investors will be delighted, with the company turning in some strong numbers with its latest results. It was overall a positive result, with revenues beating expectations by 2.0% to hit US$1.1b. NCR Atleos also reported a statutory profit of US$0.60, which was an impressive 22% above what the analysts had forecast. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Taking into account the latest results, NCR Atleos' six analysts currently expect revenues in 2025 to be US$4.35b, approximately in line with the last 12 months. Per-share earnings are expected to leap 47% to US$2.56. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$4.31b and earnings per share (EPS) of US$2.55 in 2025. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates. Check out our latest analysis for NCR Atleos With the analysts reconfirming their revenue and earnings forecasts, it's surprising to see that the price target rose 12% to US$44.67. It looks as though they previously had some doubts over whether the business would live up to their expectations. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on NCR Atleos, with the most bullish analyst valuing it at US$60.00 and the most bearish at US$34.00 per share. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation. Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. One thing stands out from these estimates, which is that NCR Atleos is forecast to grow faster in the future than it has in the past, with revenues expected to display 3.7% annualised growth until the end of 2025. If achieved, this would be a much better result than the 0.5% annual decline over the past year. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 8.0% annually for the foreseeable future. Although NCR Atleos' revenues are expected to improve, it seems that the analysts are still bearish on the business, forecasting it to grow slower than the broader industry. The Bottom Line The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for NCR Atleos going out to 2027, and you can see them free on our platform here. Plus, you should also learn about the 2 warning signs we've spotted with NCR Atleos (including 1 which is concerning) . Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
